Company Profile
Elicio Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- ELTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.02 USD (-2.27%)
Close
Last updated: August 17, 2026
219M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ELTX closed down 2.27% at $3.02. No new same-company headline was identified in the current news window.
Company overview
Lymph-Node-Targeted Immunotherapies
Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue.
ELI-002 7P
ELI-002 7P is an off-the-shelf therapeutic cancer vaccine targeting seven common KRAS mutations. It is intended to generate mutation-specific T-cell responses in patients with minimal residual disease after surgery.
Pancreatic Cancer Development
The randomized Phase 2 AMPLIFY-7P study is evaluating ELI-002 7P in patients with resected, KRAS-mutated pancreatic ductal adenocarcinoma, using disease-free survival as its primary endpoint.
Future catalysts
- Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Elicio Therapeutics, Inc. (ELTX)?
Elicio Therapeutics, Inc. (ELTX) most recently closed at 3.02 USD, a -2.27% move versus the previous session.
What is the market cap of Elicio Therapeutics, Inc. (ELTX)?
Elicio Therapeutics, Inc. currently has a market capitalization of 219M USD on BioPharmSignal.
What does Elicio Therapeutics, Inc. do?
Lymph-Node-Targeted Immunotherapies Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue. ELI-002 7P ELI-002 7P is an off-the-shelf therapeutic cancer vaccine targeting seven common...
On which exchange is ELTX stock listed?
Elicio Therapeutics, Inc. (ELTX) is associated with NASDAQ, United States, Biopharma.
What is ELI-002?
Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.
Which conditions is Elicio Therapeutics, Inc. targeting with ELI-002?
Elicio Therapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Elicio Therapeutics, Inc. describe recent progress with ELI-002?
Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.
What is AMPLIFY-7P?
Pancreatic Cancer Development The randomized Phase 2 AMPLIFY-7P study is evaluating ELI-002 7P in patients with resected, KRAS-mutated pancreatic ductal adenocarcinoma, using disease-free survival as its primary endpoint.